Nucleoside analogs offer an effective treatment for infectious diseases like HBV because of their high barrier to resistance, broad spectrum of activity, and high efficiency.
PROBLEM:
Current attempts to cure HBV infections have been associated with liver toxicity.
SOLUTION:
Riboscience’s ENPP1 inhibitors and nucleoside analogs have the potential to induce curative anti-HBV immune response without causing liver toxicity.
PROBLEM:
Today’s chronic treatments for HBV infections fail to fully suppress viral replication in the liver.
SOLUTION:
Riboscience has nucleosides that have the potential for full viral suppression in the liver.